374 related articles for article (PubMed ID: 34744463)
1. The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View.
Tambaro FP; De Novellis D; Wierda WG
J Exp Pharmacol; 2021; 13():923-935. PubMed ID: 34744463
[TBL] [Abstract][Full Text] [Related]
2. Non-Covalent Bruton's Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia.
Montoya S; Thompson MC
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509309
[TBL] [Abstract][Full Text] [Related]
3. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
Aslan B; Kismali G; Iles LR; Manyam GC; Ayres ML; Chen LS; Gagea M; Bertilaccio MTS; Wierda WG; Gandhi V
Blood Cancer J; 2022 May; 12(5):80. PubMed ID: 35595730
[TBL] [Abstract][Full Text] [Related]
4. The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.
Robak T; Witkowska M; Smolewski P
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159041
[TBL] [Abstract][Full Text] [Related]
5. The potential of pirtobrutinib in multiple B-cell malignancies.
Jensen JL; Mato AR; Pena C; Roeker LE; Coombs CC
Ther Adv Hematol; 2022; 13():20406207221101697. PubMed ID: 35747462
[TBL] [Abstract][Full Text] [Related]
6. The TKI Era in Chronic Leukemias.
De Novellis D; Cacace F; Caprioli V; Wierda WG; Mahadeo KM; Tambaro FP
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959482
[TBL] [Abstract][Full Text] [Related]
7. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
8. Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.
St-Pierre F; Ma S
Blood Lymphat Cancer; 2022; 12():81-98. PubMed ID: 35911566
[TBL] [Abstract][Full Text] [Related]
9. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
10. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
11. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
[TBL] [Abstract][Full Text] [Related]
12. Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors.
Bose P; Gandhi V
Fac Rev; 2021; 10():22. PubMed ID: 33718939
[TBL] [Abstract][Full Text] [Related]
13. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
14. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Mato AR; Woyach JA; Brown JR; Ghia P; Patel K; Eyre TA; Munir T; Lech-Maranda E; Lamanna N; Tam CS; Shah NN; Coombs CC; Ujjani CS; Fakhri B; Cheah CY; Patel MR; Alencar AJ; Cohen JB; Gerson JN; Flinn IW; Ma S; Jagadeesh D; Rhodes JM; Hernandez-Ilizaliturri F; Zinzani PL; Seymour JF; Balbas M; Nair B; Abada P; Wang C; Ruppert AS; Wang D; Tsai DE; Wierda WG; Jurczak W
N Engl J Med; 2023 Jul; 389(1):33-44. PubMed ID: 37407001
[TBL] [Abstract][Full Text] [Related]
15. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato AR; Shah NN; Jurczak W; Cheah CY; Pagel JM; Woyach JA; Fakhri B; Eyre TA; Lamanna N; Patel MR; Alencar A; Lech-Maranda E; Wierda WG; Coombs CC; Gerson JN; Ghia P; Le Gouill S; Lewis DJ; Sundaram S; Cohen JB; Flinn IW; Tam CS; Barve MA; Kuss B; Taylor J; Abdel-Wahab O; Schuster SJ; Palomba ML; Lewis KL; Roeker LE; Davids MS; Tan XN; Fenske TS; Wallin J; Tsai DE; Ku NC; Zhu E; Chen J; Yin M; Nair B; Ebata K; Marella N; Brown JR; Wang M
Lancet; 2021 Mar; 397(10277):892-901. PubMed ID: 33676628
[TBL] [Abstract][Full Text] [Related]
16. SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Easaw S; Ezzati S; Coombs CC
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):697-704. PubMed ID: 37544810
[TBL] [Abstract][Full Text] [Related]
17. Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells.
Shorer Arbel Y; Katz BZ; Gabizon R; Shraga A; Bronstein Y; Kamdjou T; Globerson Levin A; Perry C; Avivi I; London N; Herishanu Y
Front Oncol; 2021; 11():646971. PubMed ID: 34055615
[TBL] [Abstract][Full Text] [Related]
18. Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data.
Isaac K; Mato AR
Cancer Manag Res; 2020; 12():2079-2085. PubMed ID: 32256115
[TBL] [Abstract][Full Text] [Related]
19. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
20. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Kriegsmann K; Kriegsmann M; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
